Orgenesis Inc Financials
This page shows Orgenesis Inc (ORGS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Orgenesis now looks defined by balance-sheet overhang, as its shrunken revenue base no longer covers direct costs.
Across recent reporting periods, revenue collapsed faster than the balance sheet shrank, falling from$34.7M to$1.0M . At the latest year-end, liabilities still towered over the operating footprint: cash had dwindled to$78K while total liabilities remained$38.9M , leaving far less commercial activity available to carry those obligations.
The revenue left in the latest year was not self-supporting: gross loss was
The cash drain came mainly from operations, not expansion spending: operating cash flow was
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Orgenesis Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Orgenesis Inc's revenue surged 95.3% year-over-year to $1.0M, reflecting rapid business expansion. This strong growth earns a score of 0/100.
Orgenesis Inc has a moderate D/E ratio of -1.04. This balance of debt and equity financing earns a leverage score of 55/100.
Orgenesis Inc's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Orgenesis Inc passes 2 of 9 financial strength tests. no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Orgenesis Inc generated $1.0M in revenue in fiscal year 2024. This represents an increase of 95.3% from the prior year.
Orgenesis Inc earned $11.44 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 40.0% from the prior year.
Cash & Balance Sheet
Orgenesis Inc held $78K in cash against $0 in long-term debt as of fiscal year 2024.
Orgenesis Inc had 5M shares outstanding in fiscal year 2024. This represents an increase of 62.2% from the prior year.
Margins & Returns
Orgenesis Inc's gross margin was -86.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 993.9 percentage points from the prior year.
Capital Allocation
Orgenesis Inc invested $263K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 87.5% from the prior year.
ORGS Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $301K-13.3% | $347K+41.1% | $246K+74.5% | $141K-14.5% | $165K+50.0% | $110K-2.7% | $113K-20.4% | $142K |
| Cost of Revenue | $313K-46.5% | $585K+8.7% | $538K+9.3% | $492K+203.7% | $162K+16.5% | $139K-95.7% | $3.2M+18.7% | $2.7M |
| Gross Profit | -$12K+95.0% | -$238K+18.5% | -$292K+16.8% | -$351K-11800.0% | $3K+110.3% | -$29K+99.1% | -$3.1M-20.9% | -$2.6M |
| R&D Expenses | N/A | $4.5M+203.8% | $1.5M-37.2% | $2.4M-21.2% | $3.0M+272.2% | $808K-77.1% | $3.5M+7.5% | $3.3M |
| SG&A Expenses | N/A | $2.7M+29.3% | $2.1M-66.0% | $6.1M+182.3% | $2.1M+72.3% | $1.2M-93.2% | $18.2M+34.7% | $13.5M |
| Operating Income | N/A | -$8.4M-97.5% | -$4.3M+52.4% | -$8.9M-32.6% | -$6.7M-201.3% | -$2.2M+91.1% | -$25.1M-27.9% | -$19.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $44K+37.5% | $32K+540.0% | $5K-68.8% | $16K+111.3% | -$141K-135.8% | $394K+333.0% | $91K-29.5% | $129K |
| Net Income | N/A | -$9.1M-2.4% | -$8.9M+8.8% | -$9.8M-47.4% | -$6.6M-77.8% | -$3.7M+85.4% | -$25.5M-31.2% | -$19.5M |
| EPS (Diluted) | N/A | $1.93 | $0.23-20.7% | $0.29 | N/A | $0.12-84.2% | $0.76-12.6% | $0.87 |
ORGS Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4M-95.4% | $29.7M-2.9% | $30.6M-1.1% | $30.9M+112.5% | $14.6M-17.0% | $17.5M-3.0% | $18.1M-75.6% | $74.2M |
| Current Assets | $761K-69.8% | $2.5M+7.3% | $2.3M+20.0% | $2.0M-52.0% | $4.1M-31.8% | $6.0M-8.5% | $6.5M-78.5% | $30.3M |
| Cash & Equivalents | $78K-61.8% | $204K+164.9% | $77K-3.8% | $80K-90.4% | $837K+1421.8% | $55K-69.4% | $180K-93.3% | $2.7M |
| Inventory | N/A | N/A | N/A | $34K0.0% | $34K0.0% | $34K0.0% | $34K-73.4% | $128K |
| Accounts Receivable | $40K-75.2% | $161K-32.9% | $240K-2.0% | $245K+178.4% | $88K+23.9% | $71K+1083.3% | $6K-100.0% | $21.3M |
| Goodwill | N/A | $1.2M0.0% | $1.2M0.0% | $1.2M0.0% | $1.2M0.0% | $1.2M0.0% | $1.2M-85.0% | $8.1M |
| Total Liabilities | $38.9M-27.5% | $53.6M+15.6% | $46.4M-20.7% | $58.5M+64.5% | $35.5M+8.0% | $32.9M+6.8% | $30.8M-52.9% | $65.4M |
| Current Liabilities | $26.9M-25.3% | $36.0M+13.7% | $31.7M+9.2% | $29.0M+76.9% | $16.4M+14.7% | $14.3M+12.5% | $12.7M-8.8% | $13.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$37.5M-56.9% | -$23.9M-54.2% | -$15.5M+44.1% | -$27.7M-32.1% | -$21.0M-36.5% | -$15.4M-20.7% | -$12.7M-246.1% | $8.7M |
| Retained Earnings | -$224.8M-10.0% | -$204.4M-4.7% | -$195.3M-4.8% | -$186.4M-5.5% | -$176.6M-3.9% | -$170.0M-2.2% | -$166.3M-18.2% | -$140.7M |
ORGS Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1M+54.7% | -$4.6M+21.6% | -$5.9M-33.0% | -$4.4M-784.7% | -$502K+57.5% | -$1.2M+80.0% | -$5.9M+18.3% | -$7.2M |
| Capital Expenditures | $0-100.0% | $58K+5700.0% | $1K-99.5% | $204K | $0-100.0% | $300K-41.3% | $511K-60.2% | $1.3M |
| Free Cash Flow | -$2.1M+55.2% | -$4.7M+20.6% | -$5.9M-27.2% | -$4.6M-825.3% | -$502K+66.1% | -$1.5M+76.9% | -$6.4M+24.6% | -$8.5M |
| Investing Cash Flow | $292K+105.6% | $142K+14300.0% | -$1K+98.5% | -$68K-9.7% | -$62K+92.6% | -$843K+43.6% | -$1.5M-14.4% | -$1.3M |
| Financing Cash Flow | $1.4M-68.5% | $4.4M-31.9% | $6.5M+80.2% | $3.6M+195.0% | $1.2M-23.3% | $1.6M-67.3% | $4.9M-17.3% | $5.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ORGS Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -4.0%+64.6pp | -68.6%+50.1pp | -118.7%+130.2pp | -248.9%-250.8pp | 1.8%+28.2pp | -26.4%+2733.8pp | -2760.2%-943.3pp | -1816.9% |
| Operating Margin | N/A | -2419.0%-691.4pp | -1727.6%+4605.7pp | -6333.3%-2251.5pp | -4081.8%-2050.0pp | -2031.8%+20154.0pp | -22185.8%-8385.8pp | -13800.0% |
| Net Margin | N/A | -2628.2%+991.3pp | -3619.5%+3306.0pp | -6925.5%-2911.6pp | -4013.9%-627.6pp | -3386.4%+19218.1pp | -22604.4%-8893.1pp | -13711.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -223.4% |
| Return on Assets | N/A | -30.7%-1.6pp | -29.1%+2.5pp | -31.6%+13.9pp | -45.5%-24.3pp | -21.3%+120.1pp | -141.4%-115.1pp | -26.3% |
| Current Ratio | 0.03-0.0 | 0.070.0 | 0.070.0 | 0.07-0.2 | 0.25-0.2 | 0.42-0.1 | 0.51-1.7 | 2.18 |
| Debt-to-Equity | -1.04+1.2 | -2.24+0.7 | -2.99-0.9 | -2.11-0.4 | -1.69+0.4 | -2.14+0.3 | -2.42-9.9 | 7.51 |
| FCF Margin | -697.0%+654.0pp | -1351.0%+1050.6pp | -2401.6%+892.7pp | -3294.3%-2990.1pp | -304.2%+1042.1pp | -1346.4%+4339.5pp | -5685.8%+317.7pp | -6003.5% |
Note: Shareholder equity is negative (-$37.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Orgenesis Inc's annual revenue?
Orgenesis Inc (ORGS) reported $1.0M in total revenue for fiscal year 2024. This represents a 95.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Orgenesis Inc's revenue growing?
Orgenesis Inc (ORGS) revenue grew by 95.3% year-over-year, from $530K to $1.0M in fiscal year 2024.
What is Orgenesis Inc's gross margin?
Orgenesis Inc (ORGS) had a gross margin of -86.3% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What are Orgenesis Inc's total assets?
Orgenesis Inc (ORGS) had $1.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Orgenesis Inc's capital expenditures?
Orgenesis Inc (ORGS) invested $263K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Orgenesis Inc's current ratio?
Orgenesis Inc (ORGS) had a current ratio of 0.03 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Orgenesis Inc's debt-to-equity ratio?
Orgenesis Inc (ORGS) had a debt-to-equity ratio of -1.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
Why is Orgenesis Inc's debt-to-equity ratio negative or unusual?
Orgenesis Inc (ORGS) has negative shareholder equity of -$37.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Orgenesis Inc's Piotroski F-Score?
Orgenesis Inc (ORGS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Orgenesis Inc?
Orgenesis Inc (ORGS) scores 9 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.